Post

New research · Neurology
Journal of the neurological sciences · 1d
StudyJournal of the neurological sciences · 2026

World brain day 2026: Brain health - Access for all.

Tissa Wijeratne, David W Dodick, Steven L Lewis, Trustees of the World Federation of Neurology
Read paper
NeurologyStudy

Over 3.4 billion people globally are affected by neurological disorders, causing leading disability.

World brain day 2026: Brain health - Access for all.

Tissa Wijeratne et al. · Journal of the neurological sciences · 2026
Background

Neurological disorders affect more than 3.4 billion people worldwide and are now the leading cause of disability globally.

more than 3.4 billion people
Results
the global count of people living with brain and nerve conditions
More results

Despite remarkable advances in neuroscience, substantial inequities remain in access to prevention, diagnosis, treatment, and rehabilitation.

World Brain Day 2026 adopts the theme "Brain Health: Access for All", calling for coordinated global action to reduce these disparities.

More results

Built around five core pillars and five strategic priorities, World Brain Day 2026 provides a practical framework for governments, healthcare professionals, researchers, patient organisations, and communities to work together towards equitable access to brain health.

“
Conclusion

The campaign reinforces a simple but urgent message: access delayed is potentially access, and brain health, denied.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Study
95%
most specialized training program leaders were open to a unified date for job offers
Case Report
81%
patients experienced lower nightmare frequency when taking once-nightly pregabalin
Cross-sectional
RR=1.72 (1.35-2.08)
Risk of Lewy body dementia diagnosis was 1.72 times higher in North East England.
Cohort Study
71.8%
children with D/EE-SWAS achieved freedom from seizures after taking ethosuximide
Study
over 80 cases
documented cases of brain and nerve conditions found in Inquisition records
Cohort Study
27.3%
the highest proportion of patients diagnosed with Charcot-Marie-Tooth disease type 1A
Guideline
“The introduction of the first anti-amyloid mAb represents a paradigm shift in the management of AD, but is not free of challenges.”
Meta-analysis
RR 1.21
extended clot-busting treatment led to a 21% higher chance of excellent recovery from stroke